Vor Biopharma (VOR) News Today $0.20 +0.02 (+9.92%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.20 +0.00 (+2.51%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock VOR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Vor Biopharma Inc. Advanced Charts - Barron'sMay 29 at 1:29 AM | barrons.comStifel cuts Vor Biopharma stock rating amid clinical and financial concernsMay 10, 2025 | investing.comJMP Securities Downgrades Vor Biopharma (VOR)May 10, 2025 | msn.comVor Biopharma draws downgrades on strategic reviewMay 9, 2025 | msn.comJones Trading cuts Vor Biopharma stock rating to HoldMay 9, 2025 | investing.comHC Wainwright & Co. Downgrades Vor Biopharma (VOR)May 9, 2025 | msn.comVor Bio Winding Down Operations, Cutting Workforce, Exploring Potential SaleMay 8, 2025 | marketwatch.comVor Biopharma: Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | finanznachrichten.deVor Biopharma stock plummets on operation wind-downMay 8, 2025 | in.investing.comVor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Shares Bought by RA Capital Management L.P.RA Capital Management L.P. lifted its stake in Vor Biopharma Inc. (NYSE:VOR - Free Report) by 74.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 39,646,039 shares of the company's stock after acquiring an additional 16,897,159 shares duringMay 3, 2025 | marketbeat.comLynx1 Capital Management LP Buys New Stake in Vor Biopharma Inc. (NYSE:VOR)Lynx1 Capital Management LP purchased a new position in shares of Vor Biopharma Inc. (NYSE:VOR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 637,218 shares of the company's stock, valued at approximatelyApril 29, 2025 | marketbeat.comVor Biopharma faces Nasdaq delisting over low stock priceApril 27, 2025 | investing.comVor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of "Buy" from AnalystsVor Biopharma Inc. (NYSE:VOR - Get Free Report) has been assigned an average recommendation of "Buy" from the seven brokerages that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1-year price target among brokers thatApril 22, 2025 | marketbeat.comVor Biopharma Inc. (NYSE:VOR) Receives Average Rating of "Buy" from AnalystsShares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have been assigned an average recommendation of "Buy" from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month target pMarch 27, 2025 | marketbeat.comVor Bio price target lowered to $5 from $12 at StifelMarch 22, 2025 | markets.businessinsider.comVor Bio price target lowered to $13 from $17.50 at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comOppenheimer Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR)Oppenheimer reissued an "outperform" rating and set a $8.00 price objective on shares of Vor Biopharma in a report on Friday.March 22, 2025 | marketbeat.comHC Wainwright Lowers Vor Biopharma (NYSE:VOR) Price Target to $13.00HC Wainwright cut their price target on shares of Vor Biopharma from $17.50 to $13.00 and set a "buy" rating on the stock in a report on Friday.March 22, 2025 | marketbeat.comStifel Nicolaus Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock PriceStifel Nicolaus dropped their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday.March 22, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Vor Biopharma (NYSE:VOR)Wedbush restated an "outperform" rating and issued a $7.00 price objective on shares of Vor Biopharma in a report on Thursday.March 21, 2025 | marketbeat.comVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company UpdateMarch 21, 2025 | finanznachrichten.deVor Bio files $350M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comVor Biopharma's (VOR) "Outperform" Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and set a $7.00 price target on shares of Vor Biopharma in a research note on Thursday.March 21, 2025 | marketbeat.comVor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company UpdateMarch 20, 2025 | globenewswire.comVor Biopharma (NYSE:VOR) Trading Down 2.7% - What's Next?Vor Biopharma (NYSE:VOR) Stock Price Down 2.7% - Here's WhyMarch 2, 2025 | marketbeat.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by AnalystsShares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have earned an average recommendation of "Buy" from the seven analysts that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective amoMarch 2, 2025 | marketbeat.comVor Biopharma: Short On Cash, Too Much Uncertainty For NowFebruary 24, 2025 | seekingalpha.comVor Bio presents research on patients participating in CGT trialsFebruary 13, 2025 | markets.businessinsider.comVor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy TrialsFebruary 13, 2025 | globenewswire.comVor biopharma's chief medical officer sells $3,498 in stockFebruary 12, 2025 | msn.comVor Biopharma revises stock option exercise pricesFebruary 6, 2025 | msn.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by BrokeragesShares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have earned a consensus rating of "Buy" from the seven analysts that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have coveFebruary 5, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Shares Down 5.6% - What's Next?Vor Biopharma (NYSE:VOR) Trading Down 5.6% - Here's What HappenedFebruary 4, 2025 | marketbeat.comVor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | globenewswire.comVor Bio files to sell 125.71M shares of common stock for holdersJanuary 22, 2025 | markets.businessinsider.comVor Bio appoints Kalir to board of directorsJanuary 8, 2025 | markets.businessinsider.comVor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of DirectorsJanuary 8, 2025 | globenewswire.comEyal C. Attar Sells 10,334 Shares of Vor Biopharma Inc. (NYSE:VOR) StockJanuary 1, 2025 | insidertrades.comVor Biopharma Inc. (NYSE:VOR) Insider Sells $12,917.50 in StockVor Biopharma Inc. (NYSE:VOR - Get Free Report) insider Eyal C. Attar sold 10,334 shares of the business's stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $1.25, for a total value of $12,917.50. Following the completion of the transaction, the insider now directly owns 81,439 shares of the company's stock, valued at approximately $101,798.75. This trade represents a 11.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.December 31, 2024 | marketbeat.comVor Bio price target lowered to $6 from $12 at JMP SecuritiesDecember 31, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Precigen (PGEN), Vor Biopharma (VOR)December 27, 2024 | markets.businessinsider.comVor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%December 27, 2024 | finance.yahoo.comVor Bio Announces $55.6 Million Private PlacementDecember 27, 2024 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by AnalystsVor Biopharma Inc. (NYSE:VOR - Get Free Report) has been assigned an average recommendation of "Buy" from the seven research firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among analysts thatDecember 17, 2024 | marketbeat.comPositive Outlook for Vor Biopharma’s Trem-cel in AML Trials Leads to Buy RatingDecember 11, 2024 | markets.businessinsider.comOptimistic Buy Rating for Vor Biopharma Based on Promising Clinical Trial Developments and Strong Financial PositionDecember 10, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Vor Biopharma (VOR)December 10, 2024 | markets.businessinsider.comVor Biopharma’s Strategic Advances and Promising Clinical Trial Results Justify Buy RatingDecember 10, 2024 | markets.businessinsider.comVor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial DesignDecember 9, 2024 | globenewswire.com Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address VOR Media Mentions By Week VOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VOR News Sentiment▼0.500.87▲Average Medical News Sentiment VOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VOR Articles This Week▼11▲VOR Articles Average Week Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMUX News Today CHRS News Today ORMP News Today XBIT News Today ZNTL News Today ADAG News Today SNTI News Today ANRO News Today MIST News Today CLLS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VOR) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VOR Stock Free VOR Stock Alerts